ClinicalTrials.Veeva

Menu
B

Bay Area Retina Associates | Walnut Creek, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Bevacizumab
RBM-007
JNJ-81201887
Pegcetacoplan
Triamcinolone Acetonide
dexamethasone
APL-2
Lampalizumab
-Ranibizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 58 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Locations recently updated

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This mean...

Enrolling
Geographic Atrophy of the Macula
Drug: Placebo
Drug: GAL-101

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-as...

Enrolling
Diabetic Macular Edema
Drug: RO7497372

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), in...

Enrolling
Neovascular (Wet) AMD
Drug: ABI-110 High Dose
Drug: ABI-110 Low Dose
Locations recently updated

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagen...

Begins enrollment in 1 month
Macular Telangiectasia Type 2 (MacTel)
Combination Product: NT-501/revakinagene taroretcel-lwey

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling
Age Related Macular Degeneration (ARMD)
Drug: Elamipretide
Drug: Placebo

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Jaeb Center for Health Research logo
Roche logo
Genentech logo
A
R
E
Janssen (J&J Innovative Medicine) logo
N
B
4

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems